Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07366866 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults.

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment increased: 48 → 56 participants
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 4 of 10 entries
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 28, 2026 to Mar 16, 2026
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is designed to evaluate the safety, tolerability, PK and PD of GenSci136 in a randomized, double-blind, placebo-controlled trial involving healthy adult participants.
Trial Details
NCT Number NCT07366866
Lead Sponsor Changchun GeneScience Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Autoimmune Disease
Related terms Autoimmune Diseases
Enrollment 56 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov